Physician profile
Julia Song
NPI 1982629010
$11,873.79
in general payments reported to CMS, 2019-2025
31 companies · $2,657 in 2025
The $2,657 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $1,445 · 2021: $1,081 · 2022: $2,118 · 2023: $1,812 · 2024: $1,524 · 2025: $2,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,992.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $2,265.27 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $1,028.66 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $961.08 | 2022-2025 | Purified Cortrophin Gel |
| Amgen INC. | $947.85 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $825.18 | 2019-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $764.47 | 2019-2021 | |
| Allergan, INC. | $711.87 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $646.62 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $602.63 | 2022-2025 | Rocklatan, Tryptyr, Eysuvis |
| Abbvie INC. | $486.39 | 2022-2025 | Vuity, Lumigan, Durysta |
| Biotissue Holdings INC. | $354.94 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $326.04 | 2019-2025 | |
| Oyster Point Pharma, INC. | $298.89 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $247.27 | 2024-2025 | Xdemvy |
| Ellexiscience | $236.73 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $218.69 | 2022-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $189.18 | 2019-2022 | |
| Ivantis, INC | $154.08 | 2020 | |
| Harrow Eye, LLC | $106.72 | 2025 | Vevye |
| Glaukos Corporation | $74.01 | 2019 | |
| Aerie Pharmaceuticals, INC. | $64.34 | 2019-2021 | |
| Rxsight INC | $58.07 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Akorn Operating Company LLC | $57.89 | 2021 | |
| Beaver-Visitec International, INC. | $55.00 | 2020 | |
| Kala Pharmaceuticals, INC. | $45.80 | 2021-2022 | |
| Shire North American Group INC | $43.37 | 2019 | |
| Sight Sciences, INC. | $27.09 | 2022 | |
| Boston Scientific Corporation | $25.59 | 2025 | Farapulse |
| New World Medical,INC. | $19.64 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $18.40 | 2022 | |
| Akorn, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.